Strategic NonClinical Solutions LLC
Common sense solutions for drug development.
biochemistry-dna-molecule.jpg

About

Smart. Experienced. Trustworthy.

 

About Strategic Nonclinical Solutions

Strategic Nonclinical Solutions designs and applies corporate strategies for businesses in the biotechnology and regulatory drug development industries. We work with companies to guide them through the process of developing and registering therapeutics, and provide professional advice on maximizing the success of drug development programs.

 
 

 
Christopher-Tenhoor.jpg

Principal

Christopher TenHoor

Proven track record for the design and execution of successful Regulatory Drug Development strategies leading to the successful commercialization of Avonex® (Japan), Amevive® (US), Tysabri® (US), and Kalbitor® (US)

Develop overall strategies for toxicology, nonclinical and clinical pharmacokinetic, bioanalytical, and clinical pharmacology activities

Provide strategic planning and tactical execution of preclinical development activities on both IND- and Registration-stage programs while ensuring activities are conducted in- line with Regulatory standards

Build and maintain a robust and sustaining pharmacology and preclinical development function; ensure appropriate resourcing

Primary author/editor of regulatory submissions including INDs/IMPDs, BLAs, MAAs, and JNDAs for the registration of pharmaceuticals for human use

Drive internal pipeline activities in collaboration with company executives and Research functional area heads

Engage in peer-review of internal and external drug candidates/targets and provide critical input to maximize viability of Development programs

 
 

Education

Doctor of Pharmacy (Pharm. D.)
The University of Michigan

Doctor of Philosophy (Pharmaceutics)
The University of Michigan

Sloan School of Management, MIT
Executive Program “Leading Innovative Enterprises-Strategies for Growth in the Life Sciences”

Tufts Center for the Study of Drug Development “Leadership for Drug Development Teams”

 

 

Publications

J.A. Kenniston, B.M. Taylor, G.P. Conley, J. Cosic, K.J. Kopacz, A.P. Lindberg, S.R. Comeau, K. Atkins, J. Bullen, C. TenHoor, B.A. Adelman, D.J. Sexton, T.E. Edwards, A.E. Nixon
Structural Basis for pH-Insensitive Inhibition of Immunoglobulin G Recycling by an Anti-Neonatal Fc Receptor Antibody
J. Biol. Chem. In press

A. Banerji, P. Busse, M. Shennak, W. Lumry, M. Davis-Lorton, H. Wedner, J. Jacobs, J. Baker, J. Bernstein, R. Lockey, H. Li, T. Craig, M. Cicardi, M. Riedl, A. Al-Ghazawi, C. Soo, R. Iarrobino, D. Sexton, C. TenHoor, J. Kenniston, R. Faucette, G. Still, H. Kushner, R. Mensah, C. Stevens, J. Biedenkapp, Y. Chyung, B. Adelman
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
N.E.J.M. 376(8): 717-728 (2017)

A.E. Nixon, J. Chen, D.J Sexton, A. Muuruganandam, A.J. Bitonti, J. Dumont, M. Viswanathan, D. Martik, D. Wassaf, A. Mezo, C.R. Wood, J.C. Biedenkapp, C. TenHoor
Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-human Primates
Front. Immunol. 6(176): 1-13 (2015)

Y. Chyung, B. Vince, R. Iarrobino, D. Sexton, J. Kenniston, R. Faucette, C. TenHoor, L.E. Stolz, C. Stevens, J. Biedenkapp, B. Adelman
A Phase 1 Study Investigating DX-2930 in Healthy Subjects
Ann. Allergy Asthma Immunol. 113(4): 460-466 (2014)

J.A. Kenniston, R.R. Faucette, D. Martik, S.R. Comeau, A.P. Lindberg, K.J. Kopacz, G.P. Conley, J. Chen, M. Viswanathan, N. Kastrapeli, J. Cosic, S. Mason, M. DiLeo, J. Abendroth, P. Kuzmic, R.C. Ladner, T.E. Edwards, C. TenHoor, B.A. Adelman, A.E. Nixon, D.J. Sexton
Inhibition of Plasma Kallikrein by a Highly Specific, Active Site Blocking Antibody
J. Biol. Chem. 289(34): 23596-608 (2014)

Z. Li, C. TenHoor, T. Marbury, S. Swan, Y. Zhu, B. Ticho
Pharmacokinetics and Pharmacodynamics of Tonapofylline in Subjects with Severe Renal Impairment and in Elderly Subjects
Int. J. Clin. Pharmacol. Ther. 49(9): 563-570 (2011)

Z. Li, C. TenHoor, T. Marbury, S. Swan, B. Ticho, M. Rogge, I. Nestorov
Clinical Pharmacokinetics of Tonapofylline: Evaluation of Dose Proportionality, Oral Bioavailability, and Gender and Food Effects in Healthy Human Subjects
J. Clin. Pharmacol. 51(7): 1004-1014 (2011)

L. Devy, L. Huang, L. Naa, N. Yanamandra, H. Pieters, N. Frans, E. Chang, Q. Tao, M. Vanhove, A. Lejeune, R. van Gool, D.J. Sexton, G. Kuang, D. Rank, S. Hogan, C. Pazmany, Y.L. Ma, S. Schoonbroodt, A.E. Nixon, R.C. Ladner, R. Hoet, P. Henderikx, C. TenHoor, S.A. Rabbani, M.L. Valentino, C.R. Wood, D.T. Dransfield
Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
Cancer Res. 69(4): 1517-1526 (2009)

D. Hutto, C. TenHoor, J. Lane, L. Bernier, R. Quander, J. Green
B Cell Hyperplasia Associated with Immunosuppression in Cynomolgus Monkeys
Veterinary Pathology 40: 624 (2003)

A.K. Vaishnaw and C.N. TenHoor
Pharmacokinetics, Biologic Activity, and Tolerability of Alefacept by Intravenous and Intramuscular Administration
J. Pharmacokinet. Pharmacodyn. 29(5-6): 415-426 (2002)

C.S. Cho, L.C. Burkly, J.H. Fechner, A.D. Kirk, T.D. Oberley, Y. Dong, K.G. Brunner, D. Peters, C.N. TenHoor, K. Nadeau. G. Yagci, N. Ishido, J.M. Schultz, M. Tsuchida, M.M. Hamawy, S.J. Knechtle
Succesful Conversion from Conventional Immunosuppression to Anti-CD154 Monoclonal Antibody Costimulatory Molecule Blockade in Rhesus Renal Allograft Recipients
Transplantation 72(4): 587-597 (2001)

S.J. Knechtle, L.C. Burkly, J.H. Fechtner, K. Brunner, Y. Dong, C.S. Cho, K. Nadeau, C. TenHoor, M.M. Hamawy
Successful Conversion from Conventional Immunosuppression to Anti-CD40L Therapy in a Non-human Primate Model
Transplantation 69: S123 (2000)

A.D. Kirk, L.C. Burkly, D.S. Batty, R.E. Baumgartner, J.D. Hering, K. Buchanan, J.H. Fechner, R.L. Germond, R.L. Kampen, N.B. Patterson, S.J. Swanson, D.K. Tadaki, C.N. TenHoor, L. White, S.J. Knechtle, and D.M. Harland
Treatment with Humanized Monoclonal Antibody against CD154 Prevents Acute Renal Allograft Rejection in Nonhuman Primates
Nat. Med. 5(6): 686-693 (1999)

J.V.S. Gobburu, C.N. TenHoor, M.C. Rogge, D.E. Frazier, D.W. Thomas, C. Benjamin, D.M. Hess, and W.J. Jusko
Pharmacokinetics/Pharmacodynamics of 5c8, A Monoclonal Antibody to CD154 (CD40 Ligand): Suppression of an Immune Response in Monkeys
J.Pharmacol. Experimental Ther. 286(2): 925-930 (1998)

S.D. Mithani, V. Bakatselou, C.N. TenHoor, and J.B. Dressman
Estimation of the Increase in Solubility of Drugs as a Function of Bile Salt Concentration
Pharm. Res13(1): 163-167 (1996)

C.N. TenHoor and B.H. Stewart
Reconversion of Fosphenytoin in the Presence of Intestinal Alkaline Phosphatases
Pharm. Res. 12(11): 1806-1809 (1995)

C.N. TenHoor and J.B. Dressman
Oral Absorption of Peptides and Proteins
S.T.P. Pharma Sciences 2(4): 301-312 (1992)

C.N. TenHoor, V. Bakatselou, and J.B. Dressman
Solubility of Mefenemic Acid Under Simulated Fed- and Fasted-State Conditions
Pharm. Res. 8(9): 1203-1205 (1991) 

 


 

Presentations

H.J. Wedner, P. Busse, A. Banerji, M. Shennak, W. Lumry, M. Davis-Lorton, J. Jacobs, J. Baker, J. Bernstein, R. Lockey, H. Li, T. Craig, M. Cicardi, M. Riedl, A. Al-Ghazawi, C. Soo, R. Iarrobino, D. Sexton, C. TenHoor, J. Kenniston, R. Faucette, J. Biedenkapp, Y. Chyung, B. Adelman
Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema
AAAAI Annual Meeting (2016)

D. Sexton, R. Faucette, C. TenHoor, J. Kenniston, J. Biedenkapp, Y. Chyung, C. Soo, R. Iarrobino, K. Chikwamba, B. Adelman
Pharmacodynamic Bioactivity of DX-2930 in Treated Hereditary Angioedema Patients
AAPS National Biotechnology Conference (2016)

M. Davis-Lorton, P.J. Busse, A. Banerji, M. Shennak, W.R. Lumry, H.J. Wedner, J.S. Jacobs, J.W. Baker, J.A. Bernstein, R.F. Lockey, H.H. Li, T.J. Craig, M. Cicardi, M.A. Riedel, A. Al-Ghazawi, C. Soo, R. Iarrobino, D. Sexton, C. TenHoor, R. Faucette, J.C. Biedenkapp, Y.H. Chyung, B. Adelman
Pharmacodynamic Effects of DX-2930 on Plasma Kallikrein in Hereditary Angioedema Patients
AAAAI Annual Meeting (2016)

S.D. Mason, J. Kenniston, S.R. Comeau, G.P. Conley, N. Kastrapeli, K. Kopacz, A.P. Lindberg, J. Cosic, M. Kivaa, J. Qiu, R. Faucette, D. Sexton, C. TenHoor, D. Gailani, S. Kent Dickeson, Q. Cheng, M. Wallisch, A. Gruber, B. Adelman, A. Nixon
Discovery and Characterization of a Highly Specific Antibody Inhibitor of Factor XIIa, and the Subsequent Generation of a Factor XIIa/Plasma Kallikrein Bispecific Antibody
ASH Annual Meeting (2015)

J. Jacobs, P. Busse,A. Banerji, M. Shennak, W.R. Lumry, M.A. Davis-Lorton, H.J. Wedner, J.W.  Baker, J.A. Bernstein, R.F. Lockey, H.H. Li, T.J. Craig, M. Cicardi, M.A. Riedl, A. Al-Ghazawi, C. Soo, R. Iarrobina,D. Sexton, C. TenHoor, R. Faucette,J.C.Biedenkapp, Y.H. Chyung, B. Adelman
Relationship Between Drug Exposure and Clinical Response Observed in the Phase 1b Study of DX-2930 in Subjects with Hereditary Angioedema
AAAAI Annual Meeting (2015)

A. Banerji, P. Busse, M. Shennak, W. Lumry, M. Davis-Lorton, J. Wedner, J. Jacobs, J. Baker, J. Bernstein, R. Lockey, H. Li, T. Craig, M. Cicardi, M. Riedl, A. Al-Ghazawi, C. Soo, R. Iarrobino, D. Sexton, C. TenHoorJ. Kenniston, R. Faucette, J. Biedenkapp, Y. Chyung, B. Adelman
Interim Analysis Results of a Phase 1b, Multiple Ascending Dose Study to Evaluate DX-2930, A Fully Human Monoclonal Antibody Inhibitor of Plasma Kallikrein in Development for Long-Term Prophylaxis of Hereditary Angioedema
EAACI Congress (2015)

W. Lumry, M. Cicardi, P. Busse, A. Banerji, M. Shennak, M. Davis-Lorton, H. Wedner, J. Jacobs, J. Baker, J.A. Bernstein, R.F. Lockey, H. Li, T. Craig, M. Riedl, A. Al-Ghazawi, C. Soo, R. Iarrobino, D. Sexton, C. TenHoor, J. Kenniston, R. Faucette, J. Biedenkapp, Y. Chyung, B. Adelman
Attack Frequency, C1-INH Function, and Levels of Cleaved Kininogen Do Not Influence the Clinical Response to DX-2930 in Patients with Hereditary Angioedema
ACAAI Annual Meeting (2015)

P. Busse, A. Banerji, M. Shennak, W. Lumry, M. Davis-Lorton, H. Wedner, J. Jacobs, J. Baker, J.A. Bernstein, R.F. Lockey, H. Li, T. Craig, M. Cicardi, M. Riedl, A. Al-Ghazawi, C. Soo, R. Iarrobino, D. Sexton, C. TenHoor, J. Kenniston, R. Faucette, J. Biedenkapp, Y. Chyung, B. Adelman
DX-2930 in Patients with Hereditary Angioedema: Final Results of a Phase 1b Study
ACAAI Annual Meeting (2015)

Y. Chung, D. Sexton, C. TenHoor, J. Kenniston, R. Faucette, R. Iarrobino, J. Biedenkapp, B. Adelman
Pharmacologic modeling to guide the DX-2930 dosing regimen in investigating long-term prophylaxis of hereditary angioedema
ACAAI Annual Meeting (2014)

Y. Chyung, B. Vince, R. Iarrobino, D. Sexton, C. TenHoor, J. Kenniston, R. Faucette, L. Stolz, J. Biedenkapp, B. Adelman
Results of a Phase 1a, Single Ascending Dose Study of DX-2930, a Human Monoclonal Antibody Inhibitor of Plasma Kallikrein Under Investigation for Long-Term Prophylaxis of Hereditary Angioedema
EAACI Congress (2014)

D.J. Sexton, J. Kenniston, R. Faucette, A.E. Nixon, C. TenHoor, Y. Chyung, B. Adelman
Comparison of plasma kallikrein inhibition by the monoclonal antibody inhibitor DX-2930 to endogenous C1-INH
AAAAI Annual Meeting (2014)

J.A. Kenniston, D.J. Sexton, D. Martik, R.R. Faucette, M. Viswanathan, N. Kastrapeli, K.J. Kopacz, G.P. Conley, A.P. Lindberg, J. Cosic, S.R. Comeau, S. Mason, M. DiLeo, J. Chen, R.C. Ladner, T.E. Edwards, C. TenHoor, B. Adelman, A.E. Nixon
Discovery and characterization of a fully human antibody inhibitor of plasma kallikrein
ASH Annual Meeting (2013)

D.J. Sexton, J.A. Kenniston, R.R. Faucette, A.E. Nixon, C. TenHoor, Y. Chyung, B. Adelman
Comparison of Plasma Kallikrein Inhibition by the Endogenous C1-Inhibitor Versus DX-2930, a Monoclonal Antibody Inhibitor
ASH Annual Meeting (2013)

D. Sexton, R. Faucette, J. Kenniston, C. TenHoor, A.E. Nixon, B.A. Adelman
Inhibition of the plasma kallikrein-kinin system activation by DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein
8th C1-INH Deficiency Workshop (2013)

D.J. Sexton, J. Kenniston, A. Lindberg, R. Faucette, A.E. Nixon, C. TenHoor, B.A. Adelman BA
DX-2930, a fully human monoclonal antibody, specifically and potently inhibits both plasma kallikrein-mediated generation of bradykinin and direct B2R activation by plasma kallikrein
EAACI Congress (2013)

D.J. Sexton, J. Kenniston, R. Faucette, A.E. Nixon, C. TenHoor, Y. Chyung, B. Adelman
Comparison of plasma kallikrein inhibition by the endogenous C1-inhibitor versus DX-2930, a monoclonal antibody inhibitor
ASH Annual Meeting (2012)

D.J. Sexton, R. Faucette, M. Viswanathan, N. Kastrapeli, K. Kopacz, G. Conley, A. Lindberg, J. Cosic, S.R. Comeau, S. Mason, J.A. Kenniston, M. DiLeo, J. Chen, R. Ladner, A.E. Nixon, C. TenHoor, B.A. Adelman
Discovery and Characterization of a Fully Human Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Treatment of Plasma Kallikrein-Mediated Edema
AAAAI Annual Meeting (2012)

D. Martik, G. Conley, J. Chen, S. Comeau, D.J. Sexton, C. TenHoor
Effect of Anti-Ecallantide Antibodies on Tissue Factor Pathway Inhibitor Function
AAAAI Annual Meeting (2011)

C TenHoor
Nonclinical Development of a Kunitz-Based Inhibitor of Plasma Kallikrein
Applied Pharmaceutical Toxicology Annual Meeting (2010)

C TenHoor
Targeting Proteases as Anti-Cancer Therapy
EORTC-NCI-AACR Annual Meeting (2008)

L. Devy, S. Rabbani, C. TenHoor, D. Rank, C. Pazmany, L. Naa, S. Nicholson, A. Muruganandam, R. Ladner, D. Dransfield, P. Henderikx
Anti-invasive, Anti-tumoral and Anti-angiogenic Efficacy of DX-2400, A Potent and Selective Antibody Inhibitor of Human MMP-14
ASCO Annual Meeting (2007)

C. TenHoor
Development of Biologics as Future Therapies
AAPS Annual Meeting (2006)

Z. Li, D. Hess, C. Gao, H. Hess, S. Kalled and C. TenHoor
Pharmacokinetics of Human BAFF-R:Fc in Normal Mice and Mice Conditioned to Develop Collagen-Induced Arthritis
AAPS Annual Meeting (2005)

J. Lansita, C. TenHoor, J. Rutkowski, D. Hutto, D., V. Palmer, C. Graff, I. Osterburg, A. Vu, J. Clarke
Developmental Reproduction Toxicity Study of LFA-3/IgG1 Recombinant Human Fusion Protein
Charles River Annual Symposium on Biotechnology Derived Therapeutics (2005)

L. Yang, Q. Yue, Y-H. Chen, and C. TenHoor
Comparison of Three In-Vitro Systems for Metabolite Identification and Profiling: Microsomes, S9, and Hepatocytes
ISSX Annual Meeting (2005)

Q. Yue, L. Yang, and C. TenHoor
Development and Validation of an LC/MS/MS Assay for the Determination of Dimethyl Fumarate in Human Plasma
ISSX Annual Meeting (2005)

J. Jiang, T. Kruger, C. TenHoor, and L. Yang
Evaluation of Protein Precipitation Plates for Sample Preparation in Discovery Bioanalysis
ISSX Annual Meeting (2005)

Y-H. Chen, Q. Yue, C. TenHoor, L. Yang
Optimizing Incubation Conditions of Cryopreserved Hepatocytes for Metabolite Identification
ISSX Annual Meeting (2005)

T. Kruger, J. Jiang, C. TenHoor, and L. Yang
Fully Automated Sample Preparation for Discovery Stage Pharmacokinetic Studies Using An Integrated Perkin-Elmer Multiprobe IIEX (MPII) and Perkin-Elmer Evolution P3 (EP3) Automated Liquid Handling (ALH) System
ISSX Annual Meeting (2005)

Z. Li, Y. Tao, K. Porter and C. TenHoor
Preclinical and Clinical Pharmacokinetics of BG9928 and Its Glucuronide Metabolite in Toxicology Species and in Humans
ISSX Annual Meeting (2005)

Z. Li and C. TenHoor
Pharmacokinetics of Human BAFF-R:Fc in Normal Mice and Mice Conditioned to Develop Collagen-Induced Arthritis
AAPS Annual Meeting (2005)

Z. Li, D. Hess, K. Gilbride, L. Gorelik, SL. Kalled and C. TenHoor
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Human BAFF-R:Fc in Healthy Mice
Pharmaceutical Sciences World Congress (2004)

Z. Li, Y. Tao, K. Porter and C. TenHoor
Cross-species Metabolism Profiling of BG9928, A Potent Antagonist of Adenosinr A1 Reeptor
ISSX Annual Meeting (2004)

C. TenHoor
A Three Month Multiple Dose Toxicity Study of Alefacept (Amevive™) in Baboons
Society of Investigational Dermatology Annual Meeting (2001)

C. TenHoor, D. Shrager, A. Vaishnaw
Tolerability, Pharmacokinetics, and Biological Activity of Alefacept (LFA-3/IgG1 Fusion Protein) When Administered as an Intravenous Infusion, Intramuscular Injection, and Intravenous Bolus
American Academy of Dermatology (2001)

C. TenHoor, S. Vaidyanathan, P. Martin, M. Rogge, D. Frazier, D. Dalgard
Evaluation of Immune Response in Nonhuman Primates
Sierra Biomedical Annual Symposium (2001)

C. TenHoor, S Vaidyanathan, G. Beattie, P. Lappin, S. Chicknas, S. Bungo
Integration of Pharmacokinetic and Pharmacodynamic Endpoints in Comparability Testing
AAPS Annual Meeting (2000)

A. Vick, I. Osterburg, S. Bungo, C. TenHoor
Maternal and Perinatal Exposure of Anti-CD154 Monoclonal Antibody (hu5c8) in Cynomolgus Monkeys
AAPS Annual Meeting (2000)

A. Vick, M. Lerner, W. Hall, M. Butt, N. Gillett, D. Frazier, C. TenHoor
Recovery of Immune Response Following Administration of an Anti-CD154 Monoclonal Antibody (HU5C8) to Cynomolgus Monkeys
SOT Annual Meeting (2000)

C. TenHoor, J. Green, M. Rogge, D. Frazier, C. Fairman, N. Gillet
Characterizationof Pharmacologic Responsiveness Across Non-Human Primate Species
Pharma Preclinical Spring Meeting (2000)

C. TenHoor, L. Burkly, C. Benjamin, D. Hess, D. Thomas, D. Frazier, M. Rogge,
The Use of Functional Markers to Characterize Effects on Immune Response in Primates
12th Primate Symposium: Toward new Horizons in Primate Toxicology (1999)

C. TenHoor
The Use of In Vivo Pharmacologic Models to Predict Clinical Dose and Regimen
AAPS Western Regional Meeting (1999)

C. TenHoor, L. Burkly, C. Benjamin, D. Hess, D. Thomas, D. Frazier, A. Kirk, N. Kenyon, N. Gillet
Species Selectivity: In Vitro Assessments and In Vivo Correlations
Safety Evaluation of Immunomodulatory Biopharmaceuticals: Can We Improve the Predictive Value of Preclinical Studies? (1999)

C. TenHoor, M. Rogge, J. Green
Practical Considerations for Drug-Drug Interaction Studies with Biological Therapeutics
Preclinical and Clinical Development of Biological Therapeutics: Focus on Pharmacokinetics and Pharmacodynamics (1999)

C. TenHoor, L. Burkly, C. Benjamin, D. Hess, D. Thomas, D. Frazier
Application of Surrogate Markers in Biotechnology
Land O’Lakes Conference on Drug Metabolism (1998)

C. N. TenHoor, S. Vanech, M. Lerner, A. Dean, A. Miller, T. Seaman, K. Yim, S. Mishra, M. Rogge
Pharmacokinetics of an Anti-CD154 Monoclonal Antibody Following Intravenous, Intramuscular, and Subcutaneous Administration in the Cynomolgus Monkey
AAPS Annual Meeting (1998)

N. Ankoma, C.N. TenHoor, B.H. Stewart, and J.P. Hinton
Comparative PK/BIO Evaluation of 2 CCK-B Receptor Antagonist Prodrugs in Rats
AAPS Annual Meeting (1997)

J.V.S. Gobburu, C.N. TenHoor, M.C. Rogge, D.E. Frazier, D.W. Thomas, C. Benjamin, D.M. Hess, and W.J. Jusko
Pharmacokinetics/Pharmacodynamics of 5c8, A Monoclonal Antibody to CD154
AAPS Annual Meeting (1997)

N. Kenyon, L. Fernandez, M. Masetti, G. Iaria, R. Lehman, A. Ranuncoli, D. Han, M. Chatzipretrou, L. Burkly, C. TenHoor, M. Kaufmann, A. Kirk, D. Harlan, J. Wagner, L. Inverardi, R. Alejandro, C. Ricordi
Treatment with Humanized Anti-CD154 Specific Monoclonal Antibody Prolongs Islet Allograft Survival in a Preclinical, Non-Human Primate Model
International Congress on Immunosuppression (1997)

C.N. TenHoor and B.H. Stewart
The Stability of Fosphenytoin (CI-982) in the Presence of Intestinal Phosphatases
AAPS Annual Meeting (1994)